Galia Rahav
- Infectious Diseases top 0.2%
- Epidemiology top 1%
- Food Science top 1%
- Molecular Biology
- Molecular Medicine top 1%
- Co-authors
- Ohad Gal‐MorItzchak LevyGili Regev‐YochayYasmin MaorNathan KellerGili AvivYaniv LustigMichael McClelland
- Topics
- SARS-CoV-2 and COVID-19 Research (32 papers)Salmonella and Campylobacter epidemiology (22 papers)Antimicrobial Resistance in Staphylococcus (20 papers)
- Partner nations
- IsraelUnited StatesGermany
In The Last Decade
Galia Rahav
190 papers receiving 5.3k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Infectious Diseases 3.2k
- Epidemiology 1.7k
- Food Science 737
- Molecular Biology 645
- Molecular Medicine 464
Countries citing papers authored by Galia Rahav
This map shows the geographic impact of Galia Rahav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galia Rahav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galia Rahav more than expected).
Fields of papers citing papers by Galia Rahav
This network shows the impact of papers produced by Galia Rahav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galia Rahav. The network helps show where Galia Rahav may publish in the future.
Co-authorship network of co-authors of Galia Rahav
This figure shows the co-authorship network connecting the top 25 collaborators of Galia Rahav. A scholar is included among the top collaborators of Galia Rahav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galia Rahav. Galia Rahav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 9 | |
| 2 | 2 | |
| 3 | 9 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 25 | |
| 7 | 9 | |
| 8 | 9 | |
| 9 | 18 | |
| 10 | 78 | |
| 11 | 17 | |
| 12 | 18 | |
| 13 | 0 | |
| 14 | 8 | |
| 15 | 41 | |
| 16 | Phase 3 Randomized, Double-Blind Trial Evaluating Isavuconazole vs. Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Spp. or Other Filamentous Fungi (SECURE) | 4 |
| 17 | 1 | |
| 18 | 5 | |
| 19 | 19 | |
| 20 | 14 |
About Galia Rahav
Galia Rahav is a scholar working on Infectious Diseases, Endocrinology and Epidemiology, having authored 194 papers that have together received 5.4k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (32 papers), Salmonella and Campylobacter epidemiology (22 papers) and Antimicrobial Resistance in Staphylococcus (20 papers). The work is most often cited by research in Infectious Diseases (3.2k citations), Molecular Medicine (464 citations) and Endocrinology (451 citations). Galia Rahav has collaborated with scholars based in Israel, United States and Germany. Frequent co-authors include Ohad Gal‐Mor, Itzchak Levy, Gili Regev‐Yochay, Yasmin Maor, Nathan Keller, Gili Aviv, Yaniv Lustig, Michael McClelland, Prerak Desai and Victoria Indenbaum. Their work appears in journals such as New England Journal of Medicine, The Lancet and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.